The proportion of patients with early stage HER2-positive breast cancer undergoing adjuvant treatment with trastuzumab was relatively low during the first years after the introduction, only reaching 57% in 2006, which is somewhat lower than corresponding data from the Netherlands (18) but slightly higher than 50% that was reported from New Zeeland and Australia (19). This evidence concerns the gene ERBB2 and breast carcinoma.